Sanofi Initiates Vaccine Study in Canada - Analyst Blog


Sanofi 's ( SNY ) vaccines division, Sanofi Pasteur, recently announced that Cdiffense, a phase III program, has been initiated. Sanofi is working on developing a vaccine for the prevention of primary symptomatic clostridium difficile infection (CDI). The program aims to assess the safety, efficacy and immunogenicity of the CDI vaccine.

In Canada, Sanofi has started enrolling volunteers for the randomized, observer-blind, placebo-controlled, multi-center, multi-national (across 17 countries), phase III trial. The trial will enroll up to 15,000 volunteers aged ≥ 50 years, who have received systemic antibiotics in the past year and are planning to be hospitalized or were hospitalized at least twice before.

Earlier this year, Sanofi's vaccine portfolio received a boost when the European Commission approved its 6-in-1 pediatric vaccine Hexyon/Hexacima (DTaP-IPV-Hib-HepBvaccine).

The 6-in-1 vaccine is indicated for the prevention of diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis and invasive infections caused by haemophilus influenzaetype b in infants.

We note that Sanofi possesses one of the world's leading vaccine operations, with total sales of €3.9 billion in 2012. The company's portfolio includes pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi also has a strong position in both seasonal and pre-pandemic influenza vaccines. Sanofi continues to expand its vaccine business. We expect a significant ramp in vaccine sales over the next several years.

Sanofi carries a Zacks Rank #5 (Strong Sell). We are concerned about generic erosion confronting most of Sanofi's key drugs. Additionally, recent pipeline failures (oncology candidate -  iniparib and anticoagulant - otamixaban) have put immense pressure on Sanofi's pipeline.

At present, companies like Actelion Ltd. ( ALIOF ), Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look well-positioned with all three being Zacks Rank #1 (Strong Buy) stocks.


BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: ALIOF , BIIB , CDI , GILD , SNY

More from

Related Videos

What to Wear to a Wedding
What to Wear to a Wedding           
4th of July Outfits
4th of July Outfits                 



Most Active by Volume

  • $17.03 ▼ 1.10%
  • $30.555 ▲ 1.24%
  • $126.44 ▼ 0.13%
  • $40.59 ▼ 6.26%
  • $19.07 ▲ 1.54%
  • $26.78 ▲ 0.45%
  • $5.85 ▲ 1.56%
  • $8.83 ▲ 2.08%
As of 7/2/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by